Will targeting B cells be the answer for Sjögren's syndrome?


  • R. John Looney

    Corresponding author
    1. University of Rochester, Rochester, New York
    • Professor of Medicine, Department of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester, Box 695, 601 Elmwood Avenue, Rochester, NY 14642
    Search for more papers by this author
    • Dr. Looney has been an adviser to the following companies on the use of biologics in systemic lupus erythematosus, for which he has received consulting fees (less than $10,000 each), and he participates in multicenter clinical trials sponsored by several of these companies: Genentech, Biogen Idec, Roche, Amgen, Wyeth, Trubion, Coley, and MedImmune.